InvestorsHub Logo
Followers 0
Posts 7710
Boards Moderated 0
Alias Born 05/05/2020

Re: None

Wednesday, 03/02/2022 12:26:14 PM

Wednesday, March 02, 2022 12:26:14 PM

Post# of 3504
$STAB Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced submission to the U.S. Food and Drug Administration (FDA) of its pilot study protocol for STAT-205 treatment of post-acute (long-haul) COVID-19.